MTOR and hereditary clear cell renal cell carcinoma: To further confirm the efficacy of the scoring model, we integrated data from the Checkmate (KIRC) trial of renal cell carcinoma with data from a previous study article (PMID: 32472114), and then analyzed the relationship between scores and response to treatment with nivolumab (anti PD-1) versus mTOR inhibitor, as well as their relationship with patient prognosis.